Cargando…
Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting
Herceptin is the first therapy for breast cancer which targets an oncogene product. This humanized antibody to HER-2 has been shown to have activity as a single agent in a phase II trial of heavily pre-treated patients with advanced breast cancer and, in phase III studies, its use with chemotherapy...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2001
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138704/ https://www.ncbi.nlm.nih.gov/pubmed/11737889 http://dx.doi.org/10.1186/bcr326 |